CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing a novel nanomedicine that combines antioxidant therapy with clot-dissolving capabilities to treat ischemic stroke. By utilizing cerium oxide nanoparticles alongside a clinically approved drug, it aims to improve patient outcomes and reduce complications from existing treatments.
Ischemic stroke is the second cause of death worldwide.
Recombinant tissue plasminogen activator (rtPA) is the only approved therapeutic agent.
However, stroke patients often suffer from hemorrhages caused by oxidative stress, leading to high immobility rates.
The project conducted at Université Paris Cité is at the cross-section of material science and nanomedicine.
It aims to develop a nanomedicine for clot targeting, dissolution, and antioxidant therapy to treat ischemic stroke against oxidat…
UNIVERSITE PARIS CITE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
